文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

高体重指数特发性肺纤维化患者体外膜氧合支持下的结局

[Outcomes of idiopathic pulmonary fibrosis patients with high body mass index undergoing extracorporeal membrane oxygenation support].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2024-01-01
一句话结论回顾性观察显示,接受肺移植并ECMO支持的IPF患者中,高BMI(≥25.0 kg/m²)未恶化ECMO相关结局或早期预后,BMI单一参数不应作为ECMO禁忌。

该回顾性观察研究纳入2019至2020年南京医科大学附属无锡人民医院接受肺移植并ECMO支持的114例IPF患者,按BMI分为轻体重组(BMI<18.5 kg/m²,23例)、正常体重组(BMI 18.5-24.9 kg/m²,63例)和超重组(BMI≥25.0 kg/m²,28例)。超重组术前高血压(46.4% vs. 8.7%、23.8%,P<0.01)和冠心病(32.1% vs. 4.3%、20.6%,P<0.05)比例更高,其余术前、术中及ICU特征无统计学显著差异。ECMO模式、支持时间、ECMO相关并发症、ICU住院时间、机械通气时间及30天累积生存率在三组间均无统计学显著差异(均P>0.05)。作者认为高BMI不恶化ECMO相关结局或早期预后,BMI单一参数不应作为IPF患者肺移植术中ECMO使用的禁忌证。

要点

  • 超重组术前高血压比例46.4% vs. 轻体重组8.7%、正常体重组23.8%(P<0.01),冠心病32.1% vs. 4.3%、20.6%(P<0.05)。
  • ECMO模式三组无统计学显著差异:V-V模式78.3%、77.8%、78.6%;V-A模式21.7%、22.2%、21.4%。
  • ECMO支持时间(小时)轻体重组61.70±20.03、正常体重组44.57±5.76、超重组41.77±7.26,三组无统计学显著差异(P>0.05)。
  • ECMO相关并发症三组无统计学显著差异(均P>0.05):导管部位出血4.3%、7.9%、14.3%;管道内血栓8.7%、12.7%、17.9%;下肢缺血8.7%、12.7%、14.3%。
  • 30天累积生存率三组无统计学显著差异(Log-Rank检验:χ²=0.919,P=0.632)。

适用人群与场景

  • 2019至2020年南京医科大学附属无锡人民医院收治的、接受肺移植并ECMO支持的IPF患者,共114例。
  • 按BMI分组:轻体重组BMI<18.5 kg/m²(23例)、正常体重组BMI 18.5-24.9 kg/m²(63例)、超重组BMI≥25.0 kg/m²(28例)。

研究设计与关键结果

  • 研究类型:回顾性观察研究;样本量114例;单中心(南京医科大学附属无锡人民医院);人群为接受肺移植并ECMO支持的IPF患者。
  • 分组与干预:按BMI分为轻体重组(<18.5 kg/m²,23例)、正常体重组(18.5-24.9 kg/m²,63例)、超重组(≥25.0 kg/m²,28例),比较ICU期间ECMO相关结局。
  • 术前合并症:超重组高血压46.4% vs. 轻体重组8.7%、正常体重组23.8%(P<0.01);超重组冠心病32.1% vs. 轻体重组4.3%、正常体重组20.6%(P<0.05)。
  • ECMO模式:V-V模式轻体重组78.3%、正常体重组77.8%、超重组78.6%;V-A模式轻体重组21.7%、正常体重组22.2%、超重组21.4%;三组无统计学显著差异。
  • ECMO支持时间(小时):轻体重组61.70±20.03、正常体重组44.57±5.76、超重组41.77±7.26;三组无统计学显著差异(P>0.05)。
  • ECMO相关并发症(轻体重组、正常体重组、超重组):导管部位出血4.3%、7.9%、14.3%;管道内血栓8.7%、12.7%、17.9%;下肢缺血8.7%、12.7%、14.3%;均P>0.05。
  • ICU住院时间(天):轻体重组11±3、正常体重组7±1、超重组9±1;机械通气时间(天,中位数(四分位数)):轻体重组2(2, 11)、正常体重组2(2, 6)、超重组3(2, 8);三组无统计学显著差异(均P>0.05)。
  • 30天累积生存率:三组无统计学显著差异(Log-Rank检验:χ²=0.919,P=0.632)。

证据类型、等级与局限

  • 证据类型:回顾性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,高BMI不恶化接受肺移植的IPF患者ECMO相关结局或早期预后。
  • 作者认为,BMI作为单一参数不应成为IPF患者肺移植术中ECMO使用的禁忌证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the extracorporeal membrane oxygenation (ECMO) related outcomes during hospitalization during the intensive care unit (ICU) in idiopathic pulmonary fibrosis (IPF) patients with high body mass index (BMI, > 25 kg/m2) undergoing lung transplantation with ECMO support.

METHODS: A retrospective observational study was conducted. IPF patients who received ECMO during lung transplantation admitted to the Affiliated Wuxi People's Hospital of Nanjing Medical University from 2019 to 2020 were enrolled. Preoperative indicators including, demographics, comorbidities, arterial blood gas, and laboratory indicators; intraoperative indicators, such as lung lobe volume reduction, surgical type, surgical time, cold ischemia time, blood loss and transfusion volume; immediate indicators upon admission to the ICU, such as blood gas analysis and laboratory indicators; ECMO related outcomes, such as ECMO mode, ECMO support time, ECMO related complications (bleeding at the catheterization site, intraductal thrombosis, lower limb ischemia), and the length of ICU stay, duration of mechanical ventilation, and 30-day survival rate were collected. According to BMI, patients were divided into three groups: light weight group (BMI < 18.5 kg/m2), normal weight group (BMI 18.5-24.9 kg/m2), and overweight group (BMI ≥ 25.0 kg/m2). Mainly to compare the relevant outcomes of ECMO among patients during ICU.

RESULTS: A total of 114 IPF patients who received ECMO support during lung transplantation were collected, including 23 cases in the light weight group, 63 cases in the normal weight group, and 28 cases in the overweight group. Compared with patients with underweight and normal weight, overweight patients were more likely to have hypertension (46.4% vs. 8.7%, 23.8%, P < 0.01) and coronary heart disease (32.1% vs. 4.3%, 20.6%, P < 0.05) before surgery, which was consistent with international guidelines for obesity. Other clinical data (preoperative, intraoperative, ICU characteristics) showed no statistically significant differences and were comparable. There was no statistically significant difference in terms of ECMO related outcomes, such as ECMO related complications [veno-venous (V-V) mode: 78.3%, 77.8%, 78.6%, veno-arterial (V-A) mode: 21.7%, 22.2%, 21.4%], ECMO support time (hours: 61.70±20.03, 44.57±5.76, 41.77±7.26), ECMO related complications (bleeding at the catheterization site: 4.3%, 7.9%, 14.3%; intraductal thrombosis: 8.7%, 12.7%, 17.9%; lower limb ischemia: 8.7%, 12.7%, 14.3%), and the length of ICU stay (days: 11±3, 7±1, 9±1), duration of mechanical ventilation [days: 2 (2, 11), 2 (2, 6), 3 (2, 8)] among the light weight group, normal weight group, and overweight group (all P > 0.05). Kaplan-Meier survival curve analysis showed that there was no statistically significant difference in the 30-day cumulative survival rate among the three groups (Log-Rank test: χ 2 = 0.919, P = 0.632).

CONCLUSIONS: High BMI does not worsen ECMO-related outcomes or adversely affect early prognosis in IPF patients undergoing lung transplantation. BMI as a single parameter should not be a contraindication for the use of ECMO in lung transplantation surgery for IPF patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Tian J, Dong Y, Zhou T, et al. [Outcomes of idiopathic pulmonary fibrosis patients with high body mass index undergoing extracorporeal membrane oxygenation support]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 38845503. doi:10.3760/cma.j.cn121430-20231119-00989

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。